Background
==========

Cigarette smoke contains thousands of chemicals, including toxicants, which can be categorized as either gases, semi-volatiles (gas/vapor phase), or particles (\"tar\" phase) \[[@B1]\]. Machine-measured cigarette yields under the ISO testing regimen do not provide an accurate estimate of human exposure to cigarette smoke toxicants \[[@B2]\]. These limitations have led to the development of methods to quantify biomarkers for specific toxicants in biological fluids such as urine, saliva, and plasma \[[@B3]\].

The gas phase, tobacco smoke toxicant acrolein \[CAS:107-02-8\] (Figure [1A](#F1){ref-type="fig"}) has been identified by the World Health Organization (WHO) study group on Tobacco Product Regulation (TobReg) as a major contributor to smoke toxicity \[[@B4]\]. This evaluation was based on the concentration of acrolein in smoke and its toxicity potency factor (cancer and non-cancer), established using various models. 3-hydroxypropylmercapturic acid (3-HPMA) is the major urinary metabolite of acrolein (Figure [1B](#F1){ref-type="fig"}) \[[@B5]\], and it can be quantified using LC-MS based methods \[[@B3],[@B5]\].

![**Chemical structure of acrolein (**A**), 3-HPMA (**B**), and 3-HPMA-^13^C~3~-^15^N (**C**)**. 3-HPMA and 3-HPMA-^13^C~3~-^15^N molecular weights are also indicated.](1756-0500-4-391-1){#F1}

One critical element in the measurement and interpretation of biomarker data (including 3-HPMA) is the comparability in method analysis between different laboratories, which can use different methodologies. For instance, a study conducted by Biber and colleagues on a common set of urinary and plasma samples comparing nicotine and cotinine data from eleven laboratories concluded that individual values could vary significantly between laboratories \[[@B6]\]. In a more recent study, Bernert and colleagues showed that good measurement reproducibility for cotinine in a common set of samples could be achieved between six laboratories, when a standardized HPLC-UV method was used \[[@B7]\].

In this study we tested the reproducibility of 3-HPMA measurement between four laboratories using their in-house method and a common set of fortified and authentic urine samples. Each laboratory used a common reference compound and the internal standard 3-HPMA-^13^C~3~-^15^N.

Material and methods
====================

Reagents and samples
--------------------

Synthetic 3-HPMA (reference compound, Figure [1B](#F1){ref-type="fig"}) and 3-HPMA-^13^C~3~-^15^N (internal standard, Figure [1C](#F1){ref-type="fig"}) were obtained from AptoChem (Montreal, Canada). 3-HPMA-^13^C~3~-^15^N was ordered as a custom synthesis and the same lot was used by each laboratory. 3-HPMA-d~3~was supplied by Toronto Research Chemicals (North York, Canada). Pooled non-smoker urine samples were supplied fortified with 3-HPMA by RECIPE Chemicals (Munich, Germany). Four concentrations of synthetic 3-HPMA were used: unspiked (background ≈30-50 ng/ml), 400 ng/ml, 1200 ng/ml, and 3600 ng/ml 3-HPMA. Prior to distribution, the samples were quantified using one of the participating laboratories (Lab 2) in order to ensure the quality of the preparation. The samples were then portioned into 5-ml-aliquots, lyophilized and shipped to the laboratories in triplicates of each sample (3 × 4 vials with lyophilized urine). The laboratories were advised to reconstitute the samples with 5 ml water.

Five authentic urine samples, covering a 3-HPMA concentration range which reflects typical levels in non-smokers to heavy smokers, were aliquoted in triplicates and sent to the participating laboratories (3 × 5 vials). The lyophilized non-smoker urine samples were supplied by RECIPE^®^(Munich, Germany), a supplier of samples used for quality assurance testing. The smoker samples were obtained as part of a biomarker study conducted previously by BAT. The corresponding study protocol and informed consent forms were approved by the Ethics Committee of the Bayerische landesarztekammer Munich, Germany (v. 18.02.2008), which contained a provision for revisiting the samples for the purpose of biomarker method development. The clinical study was conducted in accordance with the World Medical Association Declaration of Helsinki (World Medical Association, 2004) and International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP) (International Conference on Harmonization, 1996).

Analytical procedure
--------------------

The samples were labelled with a code number and randomized prior to distribution. 10 mg of each reference compound and the internal standard were dispatched as a dried powder. Samples were received in one batch by each laboratory in September 2009, and all analyses were completed by November 2009. A summary of the analytical methods is given in Table [1](#T1){ref-type="table"}, which is based on the performance of QC samples measured prior to the initiation of the study. All four laboratories used their in-house protocol, which included a solid phase extraction step and analysis by LC-ESI-MS/MS. The methods were validated according to FDA guidelines.

###### 

Analytical method characteristics

  *Laboratories*                 *1*                    *2*                   *3*                     *4*
  ------------------------------ ---------------------- --------------------- ----------------------- --------------------
  *Method*                       LC-ESI-MS/MS           LC-ESI-MS/MS          LC-ESI-MS/MS            LC-ESI-MS/MS
  *mode*                         positive               negative              positive                negative
  *SPE (column)*                 Phenomenex Strata-X    Isolute ENV+          Waters OASIS            Waters OASIS
  *SPE recovery (%)*             74                     68                    75                      78
  *HPLC column (make)*           Waters Xterra MS C18   Waters HILIC-Silica   Waters Acquity Phenyl   Thermo BioBasic AX
  *HPLC column (size)*           50 × 2.1 mm, 2.5 μm    150 × 2.1 mm, 3 μm    100 × 2.1 mm, 1.7 μm    50 × 3 mm, 5 μm
  *Quantifier ion (mass)*        m/z 222 - 163          m/z 220 - 89          m/z 222 - 117           m/z 220 -91
  *Qualifier ion (mass)*         m/z 222 - 117          m/z 220 - 91                                  
  *precision intra-day (%)*      1.1 to 5.9             1.4 to 8.6            1.1 to 1.5              1.2 to 6.5
  *precision inter-day (%)^a^*   5.1 to 5.3             3.3 to 7              1.7 to 3.9              3.3 to 7.5
  *accuracy (%)*                 93.2 to 102            83.9 to 102           97.6 to 102             96.8 to 101
  *LOD (ng/ml)*                  2.21                   ND^d^                 ND                      ND^d^
  *LOQ (ng/ml)*                  7                      25                    50^f^                   35^f^
  *Linearity (ng/ml)*            7 to 5400              25 to 10000           50 to 5000              35 to 5000
  *Matrix effect (%)*            ND                     7.4 to 17             -1.7 to 19.6            -5.5 to 6.3

^a^Values represent the precision range obtained for low, medium, and high concentrations at the time the methods were developed, except for Lab 1 where only low and high concentrations were tested.

^b^Based on calibration standards.

^c^LOD was an estimate based on spiked water, water being used as the SPE solvent.

^d^Not determined

^e^LOQ was established in spiked water, water being used as SPE solvent.

^f^Matrices used were either diluted non-smoker urine or non-smoker urine with very low 3-HPMA background.

Statistical analysis
--------------------

Basic statistical analysis was carried out with MINITAB v15.1. Individual value plots were produced to test inter-laboratory variation of 3-HPMA concentrations. A non-parametric Wilcoxon paired t-test was performed to compare preliminary test analyses conducted with different internal standards. Analysis of covariance was used to compare the analytical methods at the four laboratories using the same internal standard (3-HPMA-^13^C~3~-^15^N). Precision statistics, as defined in ISO 5725-2 \[[@B8]\], were used as a measure of random errors, and expressed as repeatability (\'r\') and reproducibility (\'R\'). For the purposes of this study, in which each laboratory used its own method, \'R\' refers to inter-laboratory variation.

Results and discussion
======================

Data for both fortified and authentic urine, using 3-HPMA-^13^C~3~-^15^N as internal standard, were reported by each lab and the corresponding 3-HPMA concentrations (ng/ml) are shown in Table [2](#T2){ref-type="table"}. In addition, laboratory 1 repeated the measurements using two different internal standards - 3-HPMA-d~3~and 3-HPMA-^13^C~3~-^15^N - which were prepared and analyzed on the same day, in order to investigate the potential confounding effects of using different standards under the same analytical conditions. A non-parametric paired t-test showed that the use of 3-HPMA-d~3~gave consistently higher concentrations than 3-HPMA-^13^C~3~-^15^N (Figure [2](#F2){ref-type="fig"}), highlighting the importance of standardizing the use of internal standards across each laboratory throughout the study.

###### 

All urinary 3-HPMA data in ng/ml

                                       *3-HPMA (ng/ml)*                      
  ------- ------- -------------------- ------------------ ------ ----------- --------
  **1**   **a**   pooled NS^a^urine    40.6               31.9   \< LOQ^b^   \< LOQ
          **b**   pooled NS urine      29.8               30.8   \< LOQ      \< LOQ
          **c**   pooled NS urine      40.0               30.7   \< LOQ      \< LOQ
                                                                             
  **2**   **a**   fortified NS urine   466                492    396         405
          **b**   fortified NS urine   402                470    400         403
          **c**   fortified NS urine   431                471    401         402
                                                                             
  **3**   **a**   fortified NS urine   1302               1340   1180        1070
          **b**   fortified NS urine   1230               1270   1160        1140
          **c**   fortified NS urine   1140               1340   1150        1090
                                                                             
  **4**   **a**   fortified NS urine   3624               3780   3470        3220
          **b**   fortified NS urine   3714               3820   3420        3210
          **c**   fortified NS urine   3504               3970   3370        3240
                                                                             
  **5**   **a**   NS urine             39.8               48.3   \< LOQ      \< LOQ
          **b**   NS urine             48.2               46.1   \< LOQ      36.6
          **c**   NS urine             62.4               46.9   \< LOQ      35.1
                                                                             
  **6**   **a**   smoker urine         371                376    269         321
          **b**   smoker urine         376                382    294         269
          **c**   smoker urine         371                370    300         258
                                                                             
  **7**   **a**   smoker urine         870                842    613         556
          **b**   smoker urine         960                874    673         659
          **c**   smoker urine         840                830    721         619
                                                                             
  **8**   **a**   smoker urine         1080               1200   862         969
          **b**   smoker urine         1122               1160   925         914
          **c**   smoker urine         1044               1180   878         929
                                                                             
  **9**   **a**   smoker urine         1482               1390   1200        1100
          **b**   smoker urine         1296               1370   1210        1130
          **c**   smoker urine         1260               1390   1100        894

Samples are numbered from 1 to 9. Samples 1 non-smoker urine, samples 2-4 = fortified samples, and samples 5-9 = authentic urine samples. Each sample was aliquoted in triplicates labeled **a**, **b**, and **c**.

^a^NS: non smokers

^b^\< LOQ: below limit of quantification

![**Boxplot of non-parametric differences between 3-HPMA measured in all samples using 3-HPMA-d~3~and 3-HPMA-^13^C~3~-^15^N internal standards**. The hypothesis (Ho) is based on no difference (0) between the 3-HPMA-d~3~measures minus the 3-HPMA-^13^C~3~-^15^N measures. The box plot shows a clear positive difference with p = 0 based on a Wilcoxon paired t-test with a 95% confidence interval for the mean difference (x).](1756-0500-4-391-2){#F2}

A background level of 40 to 60 ng/ml 3-HPMA was observed in the non-smoker samples selected for this study. This is expected given that acrolein is also the product of lipid peroxidation, fossil fuel combustion, and is found in cooked food \[[@B9]\].

As a quality control check, data from the fortified urine samples (Table [2](#T2){ref-type="table"}) were plotted to generate a regression line and the corresponding equation. Using this, the values for the urine samples (Table [2](#T2){ref-type="table"}) were recalculated based on the 3-HPMA peak area and the 3-HPMA-^13^C~3~-^15^N internal standard. The calculated concentrations were consistent with the reported concentrations from each lab (Additional file [1](#S1){ref-type="supplementary-material"}).

Individual value plots constructed using the sample data indicate a close similarity in the measurements, across the broad range of 3-HPMA concentrations, for all four laboratories using 3-HPMA-^13^C~3~-^15^N (Figure [3](#F3){ref-type="fig"}). However, an analysis of covariance (ANOVA) indicated a significant variation between laboratories still existed (Table [3](#T3){ref-type="table"}). A closer fit could be observed between lab 1 and 2, and between lab 3 and 4. The coefficients of variation, giving an estimate of the imprecision for repeated measures at different concentration ranges, are also reported in Table [3](#T3){ref-type="table"}. The imprecision for each concentration range should be interpreted carefully since the replicate measures were obtained from three aliquots from a single solution rather than a triplicate measure of a unique sample. The fortified samples (samples 2 to 4), were used as an internal calibration reference to calculate accuracies (Table [4](#T4){ref-type="table"}).

![**Individual value plots for 3-HPMA (blue circles) (ng/ml)**. A. Value plot for the fortified samples in four laboratories. B. Value plot for authentic urine samples in four laboratories. Missing values were below the LOQ.](1756-0500-4-391-3){#F3}

###### 

One way ANOVA for 3-HPMA *vs*laboratories (lab1, 2, 3, and 4) for each set of samples

                            *Mean 3-HPMA (ng/ml)*   *StDev*   *CoV*   *P value (one-way Anova)*
  -------------- ---------- ----------------------- --------- ------- ---------------------------
  **Sample 1**   **lab1**   36.8                    6.1       16.5    0.186
                 **lab2**   31.13                   0.7       2.1     
                 **lab3**   \< LOQ                  NA        NA      
                 **lab4**   \< LOQ                  NA        NA      
                                                                      
  **Sample 2**   **lab1**   433                     32.2      7.4     0.002
                 **lab2**   477.7                   12.4      2.6     
                 **lab3**   399                     2.6       0.7     
                 **lab4**   403.3                   1.5       0.4     
                                                                      
  **Sample 3**   **lab1**   1224                    81.2      6.6     0.004
                 **lab2**   1316.7                  40.4      3.1     
                 **lab3**   1163.3                  15.3      1.3     
                 **lab4**   1100                    36.1      3.3     
                                                                      
  **Sample 4**   **lab1**   3614                    105.4     2.9     0.000
                 **lab2**   3856.7                  100.2     2.6     
                 **lab3**   3420                    50        1.5     
                 **lab4**   3223.3                  15.3      0.5     
                                                                      
  **Sample 5**   **lab1**   50.1                    11.4      22.8    0.182
                 **lab2**   47.1                    1.1       2.4     
                 **lab3**   \< LOQ                  NA        NA      
                 **lab4**   35.8                    1.1       3       
                                                                      
  **Sample 6**   **lab1**   372.4                   2.77      0.7     0.000
                 **lab2**   376                     6         1.6     
                 **lab3**   287.7                   16.4      5.7     
                 **lab4**   282.7                   33.6      11.9    
                                                                      
  **Sample 7**   **lab1**   890                     62.4      7       0.000
                 **lab2**   848.7                   22.7      2.7     
                 **lab3**   669                     54.1      8.1     
                 **lab4**   611.3                   51.9      8.5     
                                                                      
  **Sample 8**   **lab1**   1082                    39        3.6     0.000
                 **lab2**   1180                    20        1.7     
                 **lab3**   888.3                   32.7      3.7     
                 **lab4**   937.3                   28.4      3       
                                                                      
  **Sample 9**   **lab1**   1346                    119.1     8.85    0.006
                 **lab2**   1383.3                  11.5      0.8     
                 **lab3**   1170                    60.8      5.2     
                 **lab4**   1041.3                  128.5     12.3    

^g^NA: not applicable, fewer than three data points due to at least one measure \< LOQ.

###### 

Accuracies calculated for each laboratory based on 3-HPMA fortified samples at 400 ng/ml (samples 2), 1200 ng/ml (samples 3), and 3600 ng/ml (samples 4)

                                   Accuracies (%)                             
  -------------------------------- ---------------- ------------ ------------ ------------
  ***Fortified sample (ng/ml)***   ***Lab1***       ***Lab2***   ***Lab3***   ***Lab4***
                                                                              
  400 ng/ml                        108              119          99           101
  1200 ng/ml                       102              110          97           92
  3600 ng/ml                       100              107          95           90

^a^Average calculated over three independent measures

A comparison of the repeatability (\'r\'), reproducibility (\'R\'), and coefficient of variation for 3-HPMA demonstrated that within-laboratory variation was consistently lower than between-laboratory variation. The average intra-laboratory CoV was 5%, while the average inter-laboratory CoV was 12.2% (Table [5](#T5){ref-type="table"}). The average inter-laboratory coefficient of variation was 7% for the fortified urine samples and 16.2% for the authentic urine samples. These results show close comparability with those observed by Biber and colleagues, where samples spiked with cotinine had an inter-laboratory CoV ranging from 3 to 19%, while a CoV range of 4 to 59% was reported for authentic urine samples of smokers \[[@B10]\].

###### 

Repeatability, reproducibility, and intra, inter-laboratory coefficient of variation for 3-HPMA between the four participating laboratories

  *Samples*   *Mean 3-HPMA (ng/ml)^a^*   *r^b^*   *R^c^*   *CoV within (%)^d^*   *CoV between (%)^e^*
  ----------- -------------------------- -------- -------- --------------------- ----------------------
  **1**       34                         5.8      13.9     6.1                   NA^f^
  **2**       428                        50       100.8    4.2                   8.4
  **3**       1201                       142.7    261.8    4.2                   7.8
  **4**       3528                       268.4    460.3    2.7                   4.7
  **5**       45                         7.6      24.2     5.9                   NA^f^
  **6**       330                        54.9     138      6                     15
  **7**       755                        143.3    363.4    6.8                   17.2
  **8**       1021                       89.1     346.4    3.1                   12.1
  **9**       1235                       223.1    710.1    6.5                   20.5

^a^Mean of individual 3-HPMA values for all participating laboratories and for the corresponding sample set

^b^Reproducibility

^c^Repeatability

^d^composite intralaboratory coefficient of variation

^e^inter-laboratory coefficient of variation for the four participating laboratories

^f^NA: not applicable due to data \< LOQ

The overall average inter-laboratory coefficient of variation for all samples in this study was 12.2%. A CoV value higher than 10% might indicate that there is still some room for improvement; however, this seems to be in line with WHO standardized clinical methods, which in previous studies have reported average inter-laboratory coefficients of variation (CoV) above 10% \[[@B11]-[@B13]\].

The results from this first inter-laboratory comparison for the measurement of 3-HPMA in urine demonstrate a reasonably good consensus between laboratories, with an average CoV of 12.2%. However, some consistent measurement biases were still observed between laboratories, suggesting that additional work may be required to reduce the inter-laboratory CoV even further.
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###### Additional file 1

**Authentic urine 3-HPMA concentrations recalculated using a calibration curve derived from the urine samples spiked with synthetic 3-HPMA**. The 3-HPMA fortified non-smokers urine samples were used to establish 3-HPMA calibration curves for each laboratory. The concentration of 3-HPMA in authentic smokers urine was back-calculated based on the calibration curve and peak areas. The values were compared with the values obtained by each lab with their own calibration curve.

###### 

Click here for file
